Last reviewed · How we verify
M701
M701 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.
M701 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | M701 |
|---|---|
| Sponsor | Wuhan YZY Biopharma Co., Ltd. |
| Drug class | Bispecific antibody |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
M701 functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming tumor immune evasion mechanisms. By engaging dual checkpoints, the drug aims to synergistically enhance T cell activation and proliferation against cancer cells. This approach is intended to improve therapeutic efficacy compared to single-checkpoint inhibitors.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody (PHASE3)
- A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC (PHASE1, PHASE2)
- Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody (PHASE2)
- A Study of M701 (EpCAM and CD3) in Malignant Ascites (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M701 CI brief — competitive landscape report
- M701 updates RSS · CI watch RSS
- Wuhan YZY Biopharma Co., Ltd. portfolio CI